[go: up one dir, main page]

NO20070408L - Fremgangsmater og preparater ved behandling av oftalmiske tilstander med retinylderivater. - Google Patents

Fremgangsmater og preparater ved behandling av oftalmiske tilstander med retinylderivater.

Info

Publication number
NO20070408L
NO20070408L NO20070408A NO20070408A NO20070408L NO 20070408 L NO20070408 L NO 20070408L NO 20070408 A NO20070408 A NO 20070408A NO 20070408 A NO20070408 A NO 20070408A NO 20070408 L NO20070408 L NO 20070408L
Authority
NO
Norway
Prior art keywords
preparations
ophthalmic conditions
methods
derivatives
compounds
Prior art date
Application number
NO20070408A
Other languages
English (en)
Inventor
Kenneth J Widder
Jay Lichter
Nathan L Mata
Original Assignee
Sirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34981643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070408(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirion Therapeutics Inc filed Critical Sirion Therapeutics Inc
Publication of NO20070408L publication Critical patent/NO20070408L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forbindelser representert ved formel (I) som medfører reversibel nattblindhet kan anvendes til å behandle oftalmiske tilstander forbundet med overproduksjon av avfallsprodukter som akkumuleres under forløpet av synssyklusen. Det beskrives fremgangsmåter og preparater hvor det anvendes slike forbindelser og derivater av disse for å behandle f.eks. makuladegenerasjoner og -dystrofier, eller for å lindre symptomer forbundet med slike oftalmiske tilstander. Slike forbindelser og derivater av disse kan anvendes som ett enkelt middel ved en terapi, eller i kombinasjon med andre midler eller terapier. (I)
NO20070408A 2004-06-23 2007-01-22 Fremgangsmater og preparater ved behandling av oftalmiske tilstander med retinylderivater. NO20070408L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58229304P 2004-06-23 2004-06-23
US62969504P 2004-11-19 2004-11-19
US66090405P 2005-03-11 2005-03-11
US67240505P 2005-04-18 2005-04-18
PCT/US2005/020080 WO2006007314A1 (en) 2004-06-23 2005-06-06 Methods and compositions for treating ophthalmic conditions with retinyl derivatives

Publications (1)

Publication Number Publication Date
NO20070408L true NO20070408L (no) 2007-03-20

Family

ID=34981643

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070408A NO20070408L (no) 2004-06-23 2007-01-22 Fremgangsmater og preparater ved behandling av oftalmiske tilstander med retinylderivater.

Country Status (26)

Country Link
US (3) US8314152B2 (no)
EP (3) EP2025336A1 (no)
JP (1) JP4855396B2 (no)
KR (1) KR100862930B1 (no)
AR (1) AR049929A1 (no)
AT (1) ATE404188T1 (no)
AU (1) AU2005262558B8 (no)
BR (1) BRPI0512569A (no)
CA (1) CA2569691C (no)
CY (1) CY1110435T1 (no)
DE (1) DE602005008970D1 (no)
DK (1) DK1768657T3 (no)
EA (1) EA011864B1 (no)
ES (1) ES2313368T3 (no)
GE (1) GEP20084520B (no)
IL (1) IL179872A (no)
LV (1) LV13564B (no)
MX (1) MXPA06014978A (no)
NO (1) NO20070408L (no)
NZ (1) NZ551955A (no)
PL (1) PL1768657T3 (no)
PT (1) PT1768657E (no)
SG (1) SG140607A1 (no)
SI (1) SI1768657T1 (no)
TW (1) TWI396532B (no)
WO (1) WO2006007314A1 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327401A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
WO2005079774A2 (en) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
ES2644984T3 (es) 2004-06-18 2017-12-01 University Of Washington Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
MXPA06014978A (es) 2004-06-23 2007-04-25 Sirion Therapeutics Inc Metodos y composiciones parta el tratamiento de afecciones oftalmicas con derivados de retinilo.
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
EP1778207A2 (en) * 2004-08-18 2007-05-02 Sytera Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006050002A2 (en) * 2004-10-28 2006-05-11 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
WO2006052860A2 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
EA011154B1 (ru) * 2004-12-08 2009-02-27 Сирион Терапьютикс, Инк. Композиции для лечения ретинол-ассоциированных заболеваний
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
JP2009541357A (ja) * 2006-06-22 2009-11-26 シリオン セラピューティクス， インコーポレイテッド メガリン活性の調節を介した眼科的状態を処置するための方法および組成物
US20100104644A1 (en) * 2006-07-27 2010-04-29 University Of Florida Research Foundation, Inc. Compositions and Methods for Treating or Preventing Ophthalmic Disease
WO2008013983A2 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
WO2008013986A2 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic light toxicity
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
NZ587376A (en) 2008-02-11 2012-06-29 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunction
WO2009114136A2 (en) * 2008-03-12 2009-09-17 Albert Einstein College Of Medicine Of Yeshiva University Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents
US20100016218A1 (en) * 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
EP2427052B1 (en) * 2009-05-04 2015-08-26 Acucela, Inc. Compositions for use in the treatment of glaucoma or ocular hypertension
IN2012DN00352A (no) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CN102612375B (zh) 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
EP2563350B1 (en) * 2010-04-19 2020-10-14 Retinagenix Therapeutics, Inc. Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
BR112014012997A2 (pt) 2011-11-30 2017-06-13 Bikam Pharmaceuticals Inc ligantes que se ligam à opsina, composições e métodos de uso
PT2797601T (pt) * 2012-02-10 2018-06-27 Taiwan Liposome Co Ltd Composições farmacêuticas para reduzir complicações de esteroide ocular
AU2013232697B2 (en) 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2014003850A2 (en) 2012-06-26 2014-01-03 Timothy Paul Foster Methods for treatment of ocular diseases
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
WO2015184453A1 (en) * 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
CN115197160A (zh) 2014-10-24 2022-10-18 武田药品工业株式会社 杂环化合物
ES2874562T3 (es) * 2014-12-19 2021-11-05 Kemin Ind Inc Suministro intraocular de moléculas bioactivas mediante el uso de iontoforesis
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
ES2949696T3 (es) * 2016-02-15 2023-10-02 Kemin Ind Inc Liposomas cargados positivamente como portadores de moléculas lipofílicas
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
US11369695B2 (en) 2016-12-05 2022-06-28 The Jackson Laboratory Fat droplets in retina and optic nerve as a diagnostic marker for neurodegeneration and glaucoma in humans
WO2019009265A1 (ja) * 2017-07-04 2019-01-10 第一三共株式会社 視細胞変性を伴う網膜変性疾患用薬
US20220211654A1 (en) * 2019-05-06 2022-07-07 The Regents Of The University Of California Materials and methods for treating age-related macular degeneration
FR3105790B1 (fr) * 2019-12-26 2022-01-14 Biophytis Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4673044A (en) * 1985-08-02 1987-06-16 Eastman Christensen Co. Earth boring bit for soft to hard formations
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4682663A (en) * 1986-02-18 1987-07-28 Reed Tool Company Mounting means for cutting elements in drag type rotary drill bit
US4743400A (en) * 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
AU6141490A (en) 1989-07-28 1991-03-11 Sloan-Kettering Institute For Cancer Research Growth factors containing vitamin a or other retinoids and uses thereof
US5814612A (en) * 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6992108B1 (en) * 1991-12-18 2006-01-31 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US6050354A (en) * 1992-01-31 2000-04-18 Baker Hughes Incorporated Rolling cutter bit with shear cutting gage
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
US5399757A (en) * 1993-07-20 1995-03-21 Ortho Pharmaceutical Corporation Process for the preparation of N-(4-hydroxyphenyl)-retinamide
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5702357A (en) * 1995-06-07 1997-12-30 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
US5706906A (en) * 1996-02-15 1998-01-13 Baker Hughes Incorporated Superabrasive cutting element with enhanced durability and increased wear life, and apparatus so equipped
US5758733A (en) * 1996-04-17 1998-06-02 Baker Hughes Incorporated Earth-boring bit with super-hard cutting elements
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
GB9621217D0 (en) * 1996-10-11 1996-11-27 Camco Drilling Group Ltd Improvements in or relating to preform cutting elements for rotary drill bits
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US5955305A (en) * 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
AU757206B2 (en) 1997-08-15 2003-02-06 Duke University A method of preventing or treating estrogen-dependent diseases and disorders
EP1083896A4 (en) * 1998-05-11 2002-09-11 Endowment For Res In Human Bio USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
PE20010647A1 (es) 1999-09-14 2001-06-23 Lilly Co Eli Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
CA2392453C (en) 1999-11-23 2012-03-20 Gerhart Graupner Modulation of signal transduction
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
US20020143062A1 (en) 2000-10-17 2002-10-03 Board Of Regents, The University Of Texas System Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes
US6408958B1 (en) * 2000-10-23 2002-06-25 Baker Hughes Incorporated Superabrasive cutting assemblies including cutters of varying orientations and drill bits so equipped
WO2002058689A1 (en) 2000-12-05 2002-08-01 Childrens Hospital Los Angeles Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
US7166744B2 (en) 2001-05-29 2007-01-23 Chebigen Co., Ltd. Retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds
WO2003000687A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003003987A2 (en) 2001-07-06 2003-01-16 The Ohio State University Research Foundation Solid phase synthesis of arylretinamides
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20030229062A1 (en) 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US20040014131A1 (en) 2002-07-09 2004-01-22 Pfizer Inc. Assay methods
WO2004041160A2 (en) * 2002-10-30 2004-05-21 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
JP2006514094A (ja) 2002-11-29 2006-04-27 ゲーペーツェー バイオテック アクチェンゲゼルシャフト Ｃ型肝炎ウイルス感染に対して有用な製剤
SI21392A (sl) 2002-12-24 2004-06-30 Vinko Kunc Postopek za avtomatsko nastavitev ojačenja izpraševalnikovega sprejemnika v brezkontaktnem identifikacijskem sistemu
WO2004069203A2 (en) 2003-01-31 2004-08-19 Childrens Hospital Los Angeles Research Institute Oral compositions of fenretinide having increased bioavailability and methods of using the same
FI20030426L (fi) 2003-03-24 2004-09-25 Tomi Jaervinen Syklodekstriinikompleksit
US7178609B2 (en) * 2003-08-19 2007-02-20 Baker Hughes Incorporated Window mill and drill bit
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
WO2005077176A1 (en) 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
WO2005079774A2 (en) * 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (en) 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
ES2644984T3 (es) 2004-06-18 2017-12-01 University Of Washington Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
MXPA06014978A (es) 2004-06-23 2007-04-25 Sirion Therapeutics Inc Metodos y composiciones parta el tratamiento de afecciones oftalmicas con derivados de retinilo.
US7286860B2 (en) 2004-07-23 2007-10-23 Dyna Llc Systems and methods for a comfortable wireless communication device
EP1778207A2 (en) 2004-08-18 2007-05-02 Sytera Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006052860A2 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
EA011154B1 (ru) * 2004-12-08 2009-02-27 Сирион Терапьютикс, Инк. Композиции для лечения ретинол-ассоциированных заболеваний
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding

Also Published As

Publication number Publication date
JP4855396B2 (ja) 2012-01-18
CA2569691A1 (en) 2006-01-19
GEP20084520B (en) 2008-10-27
WO2006007314A1 (en) 2006-01-19
IL179872A (en) 2013-01-31
US20110294891A1 (en) 2011-12-01
CY1110435T1 (el) 2015-04-29
EA200700109A1 (ru) 2007-10-26
AU2005262558A1 (en) 2006-01-19
EP1768657B1 (en) 2008-08-13
KR100862930B1 (ko) 2008-10-13
JP2008504257A (ja) 2008-02-14
LV13564B (en) 2008-02-20
AU2005262558B8 (en) 2008-04-10
CA2569691C (en) 2010-08-17
AU2005262558B2 (en) 2008-03-20
PT1768657E (pt) 2008-11-25
EP2277516A1 (en) 2011-01-26
AR049929A1 (es) 2006-09-13
ES2313368T3 (es) 2009-03-01
US8410168B2 (en) 2013-04-02
NZ551955A (en) 2010-08-27
KR20070074541A (ko) 2007-07-12
EA011864B1 (ru) 2009-06-30
PL1768657T3 (pl) 2009-01-30
BRPI0512569A (pt) 2008-03-25
US20100298443A1 (en) 2010-11-25
IL179872A0 (en) 2007-05-15
DE602005008970D1 (de) 2008-09-25
MXPA06014978A (es) 2007-04-25
EP2025336A1 (en) 2009-02-18
HK1107671A1 (en) 2008-04-11
TW200612891A (en) 2006-05-01
DK1768657T3 (da) 2008-12-01
ATE404188T1 (de) 2008-08-15
US20060167088A1 (en) 2006-07-27
SG140607A1 (en) 2008-03-28
EP1768657A1 (en) 2007-04-04
TWI396532B (zh) 2013-05-21
US8314152B2 (en) 2012-11-20
SI1768657T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
NO20070408L (no) Fremgangsmater og preparater ved behandling av oftalmiske tilstander med retinylderivater.
NO20080718L (no) Preparat for behandling av oftalmiske lidelser via serumretinol, serumretinol-bindingsprotein (RBP) og/eller serumretinol-RBP-modulering
WO2007150046A3 (en) Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
WO2009042444A3 (en) Methods and compounds for treating retinol-related diseases
WO2008069889A3 (en) Methods of treating hemolytic anemia
NO20064660L (no) Nye forbindelser som opioid-reseptormodulatorer
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
WO2007081974A3 (en) Viral hepatitis treatment
WO2007027532A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2008013984A3 (en) Compositions and methods for treating or preventing ophthalmic disease
WO2008013986A3 (en) Compositions and methods for treating or preventing ophthalmic light toxicity
GB2442915B (en) Perylenequinone derivatives and uses thereof
NO20045215L (no) Anvendelse av tio-oxindolderivater for behandling av hudlidelser
WO2008112647A3 (en) Nitroxide radical as a treatment for neurodegeneration
WO2018191482A3 (en) Methods of treating developmental encephalopathies
NO20090282L (no) Syklopropylaminderivater som histamin H3 reseptormodulatorer
WO2009114729A3 (en) Compounds, compositions and methods for treating lysosomal storage diseases and disorders
NO20080372L (no) Pyrazolderivater som teraputiske midler
NO20060360L (no) Nye 8-azabisyklo [3.2.1] oktanderivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer
WO2007046083A3 (en) Compositions for treatment of eye diseases
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
NO20082838L (no) 9-klor-15-deoksyprostaglandinderivater, fremgangsmate for fremstilling av disse, og anvendelse som medikamenter
MY202857A (en) Method of treating hyperglycemia
NO20085412L (no) Pyrrolidinderivater som har aktivitet ved GLYT1 transportoren
UA86981C2 (ru) Применение производных ретинила для лечения офтальмических состояний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application